INTRODUCTION
The pharmacological inhibition of the ALK (Anaplastic Lymphoma Kinase) tyrosine kinase has become in the last years an issue of great interest, given its involvement in different malignancies and the recent development of several ALK inhibitors. ALK oncogenic role was recognized for the first time in the midnineties, (1) , when the NPM-ALK fusion protein was identified as the main cause of a particular subset of Anaplastic Large Cell Lymphoma (ALCL). After that, other oncogenic fusion proteins involving the functional ALK kinase domain have been described in different kinds of both solid and haematological tumors, such as 50% of Inflammatory Myofibroblastic Tumors (IMT) (2) , about 5% of cases of Non Small Cell Lung Cancer (NSCLC) (3) , and at low frequency in other types of tumor, such as Rhabdomyosarcoma (RMS)(4), Extramedullary Plasmacytoma(5), Renal Cell Carcinoma(6), Thyroid Cancer(7), Basal Cell Carcinoma (8) , Breast Cancer and Colorectal Cancer (9, 10) . Moreover, aberrant activation or overexpression of full-length ALK has an oncogenic role in neuroblastoma (11, 12) and glioblastoma multiforme (13, 14) . The oncogenic properties of aberrantly activated ALK are mainly due to the deregulated activation of different downstream pathways such as RAS/RAF/MEK/ERK1/2 and PCLγ, involved in cellular proliferation, and PI3K/AKT and JAK3/STAT3, that promote cell survival (15) (16) (17) . The first clinically available drug able to efficiently target ALK was the dual ALK and MET inhibitor Crizotinib, now approved for the treatment of late stage and metastatic ALK+ NSCLC and in clinical trial for other ALK-related diseases. The latest clinical data about ALK+ NSCLC patients treated with Crizotinib reveal an increase of median progression free survival (PFS) and response rate compared to chemotherapy. No significant advantage in overall survival (OS) was observed, however Crizotinib treated patients had a better quality of life (18) . Very limited data are available on ALCL patients (19) . The first long term follow up of ALCL patients who received Crizotinib reported, after two years, a PFS of 63.7% and an OS of 72.7% and the drug was in general well tolerated (20) . However, despite great success, as expected from previous experience with tyrosine kinase inhibitors (21, 22) , the first cases of relapse due to the positive (20, (23) (24) (25) (26) . In order to effectively overcome Crizotinib resistance, the development of second generation ALK inhibitors is exponentially growing (27) . Currently, several ALK inhibitors are already in clinical trial: the phase I/II AP26113 (Ariad), the phase II/III LDK-378 (Novartis), the phase I/II CH5424802 (Roche) and the phase I ASP3026 (Astellas). In this work, we decided to focus our attention on the dual ALK/EGFR inhibitor AP26113 because, after Crizotinib, it was the first inhibitor entered in clinical trials.
Preclinical data showed that this inhibitor is 10 fold more potent than Crizotinib and active against the gatekeeper mutant L1196M. In xenograft mouse model lower AP26113 doses compared to Crizotinib lead to complete tumor disappearance (28) . Unfortunately, the chemical structure remains undisclosed.
In this paper we selected 8 new human NPM-ALK+ cell lines, 4 derived from KARPAS-299 and 4 from SUP-M2, able to live and proliferate at high AP26113 doses (K299AR300A, K299AR300B, K299AR300C, K299AR300D, SUP-M2AR500A, SUP-M2AR500B, SUP-M2AR500C, SUP-M2AR500D). For KARPAS-299-derived cell lines we observed oncogene overexpression as the main resistance mechanism, while in SUP-M2-derived cell lines we identified several point mutations located within the NPM-ALK kinase domain, that could explain drug resistance. We also found a L1196M mutation in two out of four SUP-M2-derived cell lines, but it had no role in conferring resistance at high drug doses. In order to find a way to overcome AP26113 resistance we explored the cross-resistance of our KARPAS-299 derived cell lines and mutated Ba/F3 NPM-ALK against other clinically relevant ALK inhibitors nowadays available, namely Crizotinib, LDK-378, CH5424802, ASP3026. KARPAS-299 derived cell lines are highly resistant to all inhibitors tested, while all mutants studied were targetable with at least a compound, except S1206C.
Collectively, our data predict in a human cell-based model the appearance of different mechanisms of resistance to AP26113 , and we explored different ways to overcome resistance using a set of clinically relevant ALK inhibitors. This kind of knowledge is a powerful tool to manage clinical cases of Crizotinib and AP26113 relapse. 
MATERIALS AND METHODS

Cell lines, inhibitors and selection of AP26113 resistant cell lines
The human NPM-ALK+ KARPAS-299 and SUP-M2 cell lines bearing the t(2;5) translocation and the pro-B murine cell line Ba/F3 were purchased from DSMZ, where they are routinely verified using genotypic and phenotypic testing to confirm their identity Cell lines were subcultured as previously described (29) . AP26113 was kindly provided by Ariad Pharmaceutical and added to the medium initially at 20 nmol/L. Medium was replaced with fresh RPMI-1640 supplemented with AP26113 every 48 or 72 hours, and cell number and viability were assessed by Trypan Blue count. Ba/F3 cells were maintained in RPMI medium supplemented with 10% foetal bovine serum and CHO cells supernatant (1:2000) as a source of IL-3. Ba/F3 cells were transduced with mutagenized pcDNA3.0-NPM/ALK plasmid (see below) by electroporation, as previously described (29) and selected first with G418 (Euroclone) 2mg/mL, followed by IL-3 withdrawal. Crizotinib was kindly provided by Pfizer, LDK-378 by Novartis, ASP3026 by Astellas while CH5424802 was purchased from Selleck Chemicals.
Site-directed mutagenesis
pcDNA3.0 bearing human WT NPM-ALK (pcDNA3.0 NA) was kindly provided by Dr. S. W. Morris 
Fluorescence In Situ Hybridization (FISH)
Interphase FISH was performed using ALK Dual Color Break Apart Rearrangement Probe(Cytocell). This probe consists of a green 420Kb probe, which span the majority of the ALK gene and a red 486 Kb probe, which is telomeric to the ALK gene. Slides were prepared following standards cytogenetics procedures.
Codenaturation/hybridization of the specimen slides and probes were performed at 72°C for 2 min and at 37 °C overnight, followed by washing in SSC solutions and counter-staining with anti-fade solution containing DAPI
PCR , quantitative RT-PCR and sequencing
An NPM-ALK fragment encompassing the breakpoint and comprising the whole kinase domain was amplified by PCR using high fidelity Taq polymerase (Roche), according to instructions. Primers used were FW: 5'-TGCATATTAGTGGACAGCAC -3'; REV:5'-CTGTAAACCAGGAGCCGTAC -3'. PCR products were sent to Eurofins MWG Operon for sequencing. Quantitative real time PCR (qPCR) was performed as previously described (29) . Housekeeping genes used for normalization were murine HPRT FW: 
Bioinformatics
Image processing and base calling were performed using the Illumina Real Time Analysis Software RTA v1.9.35 or newer. Qseq files were deindexed and converted to the Sanger FastQ file format using inhouse scripts. FastQ sequences were aligned to the human genome database (NCBI Build 36/hg18) using the Burrows-Wheeler-based BWA alignment tool. The alignment files (SAM format) were processed with SAMtools (30): they were initially filtered by proper-pair, then converted into the binary BAM alignment format, sorted and indexed. Removal of duplicates was performed using the SAMtools rmdup command. Unique BAM files were then converted into the mPileup format. mPileup data generated from paired cancer and control samples were cross-matched using a dedicated in-house software tool.
Copy number and allelic imbalance/loss of heterozigosity analyses from whole-exome data were performed using CEQer (31) .
Western blotting and antibodies
Cells were seeded in complete medium in 12-well plate and compounds were added at different 
RESULTS
Establishment and characterization of human AP26113-resistant cell lines.
To obtain a reliable resistance model we grew two different human NPM-ALK positive cell lines, KARPAS-299 and SUP-M2, in the presence of increasing AP26113 doses (29) . We divided each cell line into four different flasks, assuming that a stochastic selection would occur in each independent population. Cell were assessed by western blot (Fig.1, fig. suppl . 7A) using specific antibodies for total ALK and phosphorylated ALK (Tyr 1604). While in parental cells 100nM AP26113 completely abrogates ALK activation, in all resistant populations Tyr 1604 phosphorylation is still detectable at 100 or even 300 nM, indicating that drug resistance is due to a mechanism that directly impairs ALK inactivation. 
Identification of Resistance mechanism
Western Blot analysis revealed an increase in NPM-ALK expression, quantified by densitometry as 9.4±2.1, 6.0±1.3, 7.1±1.8 and 6.5±0.5 fold compared to parental cells for K299AR300A, K299AR300B, K299AR300C and K299AR300D cells, respectively ( fig. suppl.2) . Notably, in the first three cell lines (A, B and C) the basal phospho-ALK signal was higher than in parental cells (Fig.1A) . This hyper-activation could be simply due to the increased NPM-ALK expression rather than to an intrinsic NPM-ALK hyper- (Fig.2B) . Since the IC 50 value observed for all resistant cell lines is extremely high, we explored the presence of low frequency point mutations in ALK kinase domain as an additional resistance mechanism by deep sequencing. The results excluded this hypothesis (data not shown). NPM-ALK overexpression in K299AR300D was less evident than in the other cell lines. Moreover, the band corresponding to P-Tyr1604 ALK disappears at 300nM, suggesting low molecular resistance to AP26113, despite the fact that STAT-3 phosphorylation remains also at high drug doses and the cells RR index was 180. Whole exome sequencing and copy number analysis of this cell line highlighted that the increase in ALK expression was due to NPM-ALK amplification. In addition, some huge copy number alterations 
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were present. Also missense mutations were detected but none of them involved proteins clearly related to tumorigenesis or drug resistance ( fig. suppl.3 ).
Also in SUP-M2 derived resistant cells we could observe a great increase in IC 50 value compared to SUP-M2 parental cell line, and, as expected, this corresponded to a persistent P-Tyr1604 ALK signal (Fig.1, fig. suppl.7A). No increase in total ALK or in basal ALK phosphorylation was evident in SUP-M2 derived cell lines (tab.2, fig.1B, fig 2A) . We speculated that SUP-M2 resistance could be due to the positive selection of point mutations in the NPM-ALK kinase domain, so a fragment comprising the whole kinase domain from total RNA was amplified after retrotranscription and analyzed by direct sequencing. In all resistant SUP-M2 derived cell lines we found at least one point mutation as a possible resistance mechanism (table3, fig.2C ). Moreover, STAT-3 was still phosphorylated at the highest AP26113 dose (Fig.1B) , confirming an aberrant upregulation of NPM-ALK driven signalling. To confirm the role of these point mutations in resistance to AP26113, all of them were introduced into the pro-B murine Ba/F3 cell line expressing human NPM-ALK model ( fig. suppl 4) . The AP26113 IC 50 value was also calculated for the Ba/F3 cell line together with the assessment of NPM-ALK P-Tyr1604 and STAT3 P-Tyr 705 phosphorylation status in the presence of increasing drug doses (Tab 4A, 4B, fig.3, fig. suppl.7B ). All mutants, except L1196M, showed intermediate to high resistance to AP26113, paralleled by persistent NPM-ALK phosphorylation. These data confirmed an effective role for these mutations in AP26113 resistance, except for the gatekeeper substitution L1196M. Clonal sequencing of SUP-M2AR500A
showed the simultaneous presence of two mutations: F1174V and L1198F (tab.5A), while in SUP-M2AR500B cell line revealed the simultaneous presence of L1196M and at least another substitution, mainly L1122V, found in 80% of clones analyzed, but also D1203N (6.7%) (tab.5). Notably, F1174V alone was unable to confer AP26113 resistant, while the double mutant F1174V+L1198F was highly resistant to the same compound. Similarly L1122V alone was sufficient to induce AP26113 resistance (tab.4), thus supporting the idea that this was the effective driver mutation, as well as the L1198F for the previous 
double mutant. Moreover we could not select, after two experiments, a Ba/F3 cell line expressing the single NPM-ALK D1203N able to survive in the absence of interleukin 3. Moreover, the double L1196M+D1203N mutant is highly AP26113 resistant, so it is possible that both mutations are required for an advantageous selection and drug resistance. We detected also the presence of the P1139S mutation in one clone out of 15, but it is not able to confer high AP26113 resistance (IC50=0.015 ʅM, RR index=2.14). Interestingly F1174V and L1198F mutations were not able to induce resistance to AP26113 singularly, but their cooperation was necessary.
Cross-resistance to other ALK inhibitors
To explore a possible way to overcome AP26113 resistance we tested the sensitivity of KARPAS-derived cell lines and mutated NPM-ALK expressing Ba/F3 cells to other clinically relevant ALK inhibitors:
Crizotinib, LDK-378, CH5424802 and ASP3026. As expected, all KARPAS-299 derived cell lines are highly resistant to all inhibitors, according to the proliferation assay (tab.6). These data are consistent with the observation that in K299AR300A, B and C cell lines a general mechanism of drug resistance, oncogene amplification, has been selected.
We also challenged Ba/F3 NPM-ALK WT and mutated cell lines with all the ALK inhibitors (Tab.4A-4B).
Cells carrying the NPM-ALK L1122V mutation are moderately resistant to Crizotinib and resistant to CH5424802, LDK378 and ASP3026 (RR index is 2.6, 5.3, 9.1 and 4.9 respectively); our data about the gatekeeper mutant L1196M suggest a moderate resistance to AP26113, Crizotinib and CH5424802 (RR = 2.1, 3.4 and 2.9), confirming our previous data (29) , resistance against ASP3026 and sensitivity to LDK- In conclusion, according to these data, we can foresee that for each mutation, alone or in combination, except S1206C, there is a clinically available ALK inhibitor able to overcome acquired resistance to perform any molecular modelling analysis. Residue L1122 is located at the P-loop and extends into the drug binding pocket ( fig. suppl.6 ). To our knowledge, mutations involving this residue have never been observed thus far, neither for Crizotinib nor for AP26113 resistance. It is interesting to note that L1122 corresponds to Abl L248, whose substitution with valine or with arginine causes resistance to several TKIs (33) . The gatekeeper L1196M was one of the first causes of Crizotinib resistance found in patients.
A moderate AP26113 resistance was predicted in vitro (29, 34, 35) , however the IC 50 value is low enough to consider this mutation sensitive to AP26113. Because in SUP-M2AR500B cells both L1122V and L1196M were found, we hypothesize that the first is the mutation driving resistance, while the latter was selected at low doses and never counterselected, remaining as a passenger in the high-doseresistant clone. Topo-cloning performed on SUPM2AR500B cell line supported this hypothesis, in fact both mutations are simultaneously present in 12 out of 15 clones (80%), moreover, where L1122V is not detected, the D1203N is present (13% of cases), highlighting the weakness of L1196M in conferring AP26113 resistance (tab. 5B). The fact that we could not establish an IL3 independent Ba/F3 NPM-ALK D1203N cell line means that this mutation alone is disadvantageous. However the double L1196M+D1203N mutant was not only able to growth upon IL-3 withdrawal but also showed high AP26113 resistance, thus highlighting the fact that a cooperation between the two single mutations is favourable for drug resistance. Curiously, the double mutant is targetable by ASP3026 while the single L1196M is not, but it is moderately resistant or resistant to all other inhibitors. P1139S alone, unique in SUP-M2AR300B clone #9, is sensitive to AP26113 (RR index = 1.8), thus we can speculate that, in this clone, other unknown mechanisms may cooperate in its positive selection. F1174 is located at the end of the αC helix ( fig. suppl.6 ) and lies in a hydrophobic cluster composed by F1098, F1271 and F1245.
Mutations involving F1174 were recognized as activating in neuroblastoma and phenylalanine substitution with a leucine was found in an IMT patient that relapsed after Crizotinib treatment (24) . 
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AP26113 100nM and 200nM in a previous Ba/F3 screen (34) . In our screening, Ba/F3 cells bearing the single mutation are completely sensitive to all drugs studied, including AP26113. L1198F alone in our Ba/F3 cells was sufficient to confer resistance to AP26113, CH5424802, LDK-378 and ASP3026, however it was completely sensitive to Crizotinib. A methionine substitution in this position was predicted to confer resistance at AP26113 at 100nM(34), whereas a proline was predicted to confer crizotinib resistance in an in vitro screening (36) . This residue corresponds to the Abl F317, a site that, if mutated, induces resistance to several TKIs. Notably, in our model L1198F and F1174V cooperate in conferring resistance against AP26113. Finally, S1206 is located into the αD helix. A tyrosine substitution was found in a NSCLC patient that relapsed after Crizotinib treatment, while substitutions with an arginine, an isoleucine or a glycine were predicted in vitro as resistant to AP26113. Notably the S1206R was the only mutation detected at AP26113 500nM, indicating that this residue has a key role in conferring high AP26113 resistance (34) . All data obtained by 3 H thymidine incorporation test were validated by western blot (fig 1, fig.3 another inhibitor, already available in clinic. In the light of these data, we could speculate that most of the efforts should be directed in finding a new inhibitor, able to target mutations involving the S1206 residue. This knowledge, together with all data nowadays available on Crizotinib resistance, is a useful tool to manage cases of AP26113 resistance, both for the oncologist and for the drug designer. 
